Načítá se...
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2018
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/ https://ncbi.nlm.nih.gov/pubmed/30480763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|